Keeping those telomeres short! an innovative intratumoral long-term drug delivery system
- 30 July 2014
- journal article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 141 (1) , 23-34
Abstract
Telomerase activation and an alternative lengthening of telomeres (ALT) mechanism are two telomere-lengthening cancer cell survival mechanisms elicited by both chemo- and/or radiotherapy. Telomere lengthening interferes with cell lethality and results in the immortalization of cancer cells. To counteract these mechanisms, we developed a drug delivery system (DDS) consisting of a polymeric implant that is inserted directly into tumors. The DDS releases, continuously and gradually, a cationic porphyrin (PdTMPyP4) for >30 days after a single application, and inhibits telomerase activation. The PdTMPyP4 porphyrin is incorporated into a poly(co-glycolic lactic)acid (PLGA) polymer, solidified and cut into small rods. PdTMPyP4 release from the rods was measured spectrophotometrically over time. Uptake of Pd in the DNA of in L428 Hodgkins lymphoma cells was measured by ICP-MS, and telomerase activation by the TRAP assay. The rods were placed into the growth medium of cells whose growth rate was measured for 11 and 19 days. The cylinders were also inserted directly into KHJJ murine mammary tumors borne on the thighs of BALB/c mice and the tumor growth rate measured. In vitro, >109Pd atoms were measured in the DNA of each L428 cell and telomerase activity was reduced by ~15 % within 24 h. A one-time application of the rod in the cell medium induced a factor of >5 greater lethality compared to a blank rod or untreated controls. In vivo, a one-time insertion of the rod into tumors resulted in the retardation of the growth rate by factors of 3–5 compared to untreated controls. Systemic uptake after intratumoral insertion of the rod was negligible. The results suggest that the direct intratumoral insertion of a PdTMPyP4-containing polymeric rod would be of benefit as an adjuvant treatment for patients undergoing chemo- or radiotherapy. By preventing the lengthening of telomeres and therefore the unrestricted growth of cancer cells, our DDS will provide a significant therapeutic advantage to these treatments without affecting normal tissues.Keywords
This publication has 65 references indexed in Scilit:
- Photon activation therapy of RG2 glioma carrying Fischer rats using stable thallium and monochromatic synchrotron radiationPhysics in Medicine & Biology, 2012
- Antitelomerase Therapy Provokes ALT and Mitochondrial Adaptive Mechanisms in CancerCell, 2012
- Molecular and cellular radiobiological effects of Auger emitting radionuclidesRadiation Protection Dosimetry, 2010
- Thermodynamic Stability and Folding Kinetics of the Major G-Quadruplex and Its Loop Isomers Formed in the Nuclease Hypersensitive Element in the Human c-Myc Promoter: Effect of Loops and Flanking Segments on the Stability of Parallel-Stranded Intramolecular G-QuadruplexesBiochemistry, 2010
- Association of telomerase activity with radio- and chemosensitivity of neuroblastomasRadiation Oncology, 2010
- Interaction of Metal Complexes with G‐Quadruplex DNAAngewandte Chemie International Edition, 2010
- Telomere Shortening Sensitizes Cancer Cells to Selected Cytotoxic Agents: In Vitro and In Vivo Studies and Putative MechanismsPLOS ONE, 2010
- Cell Proliferation in the Presence of TelomerasePLOS ONE, 2009
- RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cellsBMC Cancer, 2009
- Telomerase inhibition in a mouse cell line with long telomeres leads to rapid telomerase reactivationExperimental Cell Research, 2008